Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication

Tumor-Agnostic Indication Approved In The US

Executive Summary

GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.

You may also be interested in...



Despite A Third Failure, Merck KGaA And GSK Won’t Give Up On Bintrafusp Yet

After three failures in quick succession, Merck needs to see a win in one of its many remaining Phase II trials.

Keeping Track: Ticovac Is Latest Win For Pfizer’s Vaccine Business; Doors Open For BMS And GSK PD-1 Inhibitors

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone

GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel